Humanin vs Rapamycin
A side-by-side research comparison of Humanin and Rapamycin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | Rapamycin |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | Rapamycin (Sirolimus) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | FDA-approved (off-label for longevity) |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | Inhibits mTOR complex 1 (mTORC1), reducing cellular growth signaling and activating autophagy - the cellular recycling process. Mimics caloric restriction at the molecular level. |
| Molecular weight | 2,687 Da | 914.17 Da |
| Half-life | 4-6 hours | ~62 hours |
| Bioavailability | Moderate (SubQ) | ~14% oral |
| Typical dose | 1-5 mg | 3-6 mg |
| Frequency | 3-5x per week | Once weekly |
| Route | Subcutaneous | Oral tablet |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
Rapamycin reported benefits
- Enhanced autophagy
- Immune rejuvenation
- Anti-aging cellular effects
- Cancer risk reduction
- Improved vaccine response (elderly)
- Longevity extension
Related comparisons
Research and educational reference only. Not medical advice.